SecBot SecBot
DEFA14A ·Filed Apr 22, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001104659-26-046801
Proxy solicitation materials
Actionable Insight • Neutral

Attend the virtual annual meeting on June 3, 2026 to vote on the board's recommendations. The proposals are standard governance matters with no immediate financial impact.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.56
T+0 close · Apr 22, 2026 · via day close
Latest settled
−8.22%
T+60 · $10.61
Vs SPY
−13.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $11.56entry
  2. T+1 · 7mo ago −0.43%α −1.22% · $11.51
  3. T+5 · 7mo ago −3.98%α −5.46% · $11.10
  4. T+20 · 6mo ago −5.02%α −9.65% · $10.98
  5. T+60 · 4mo ago −8.22%α −13.24% · $10.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Keros Therapeutics is holding its 2026 annual shareholder meeting virtually on June 3, 2026. The board recommends voting for the election of Jean-Jacques Bienaimé and Charles Newton as Class III directors, ratifying Deloitte & Touche LLP as auditors, and approving executive compensation.

Key Financial Metrics

Vote
director election
Meeting
2026-06-03
Seats Contested
2

Key Facts

  • Annual meeting date: June 3, 2026
  • Meeting will be held virtually
  • Board recommends voting FOR all proposals
  • Proposal 1: Elect Jean-Jacques Bienaimé and Charles Newton as Class III directors
  • Proposal 2: Ratify Deloitte & Touche LLP as independent registered public accounting firm
  • Proposal 3: Approve executive officer compensation

Financial Impact

Routine governance matters

director_electionauditor_ratificationexecutive_compensation

Risk Factors

  • Failure to ratify auditors could lead to regulatory issues
  • Shareholder opposition to executive compensation could signal governance concerns

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-046801
Document: 0001104659-26-046801-index-headers.html0001104659-26-046801
Document: 0001104659-26-046801-index.html0001104659-26-046801
Document: 0001104659-26-046801.txt0001104659-26-046801

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 22, 2026